• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Clinical management of hepatitis B virus infection correlated with liver transplantation

    2010-06-29 10:12:16JianZhangLinZhouandShuSenZheng

    Jian Zhang, Lin Zhou and Shu-Sen Zheng

    Hangzhou, China

    Clinical management of hepatitis B virus infection correlated with liver transplantation

    Jian Zhang, Lin Zhou and Shu-Sen Zheng

    Hangzhou, China

    BACKGROUND:As a radical cure for post-hepatitis B virus (HBV)-related liver cirrhosis and hepatocellular carcinoma, liver transplantation has been applied in many medical centers. Before the use of effective measures, hepatitis B recurrence and the existence of HBsAg(+) donors, patients with hepatitis B-related diseases are contraindicated for liver transplantation. Application of interferon, hepatitis B immunoglobulin (HBIG), and nucleotide analogues (e.g., lamivudine) has made great progress in the clinical care of HBV. However, there are still many shortcomings such as low viral suppression rate, rising expense, and the induction of HBV tyrosine-methionineaspartate-aspartate (YMDD) mutation. This article systematically reviews the current evidence that immunotherapy, conventional drug combinations, and some special fields of HBV infection correlate with liver transplantation.

    DATA SOURCES:Studies were identified by searching MEDLINE and PubMed for articles using the keywords "hepatitis B virus", "hepatitis B vaccination", "lamivudine", "adefovir", "entecavir", "tenofovir", "HBV genotype", and "liver transplantation" up to October 2009. Additional papers were identified by a manual search of the references from the key articles.

    RESULTS:Hepatitis B vaccine and human monoclonal antibody have very good clinical prospects. Compared with traditional therapies, the new medical regimens have many benefits such as boosting viral suppression rate and decreasing medical expenses. The triple therapy for YMDD mutation also has an excellent therapeutic effect and a low barrier to resistance. New nucleos(t)ide analogues (entecavir and tenofovir) eliminate virus more effectively with few adverse reactions, and may replace lamivudine or HBIG in future.CONCLUSIONS:Hepatitis B vaccine needs further largescale and rigorous randomized controlled trials to confirm its effective dose and injection frequency. Monoclonal antibody is still experimental, and the next step is to carry out the relevant animal and human studies. A consensus standard regimen for the treatment of hepatitis B should be developed.

    (Hepatobiliary Pancreat Dis Int 2010; 9: 15-21)

    hepatitis B vaccination;hepatitis B immunoglobulin; lamivudine; liver transplantation; adefovir; hepatitis B virus; genotype

    Introduction

    Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic diseases. About 2 billion people worldwide have been infected with the virus and about 350 million live with chronic infection. An estimated number of 600 000 persons die each year from the acute or chronic consequences of hepatitis B.

    Liver transplantation is a radical cure for posthepatitis B virus (HBV)-related cirrhosis and hepatocellular carcinoma. In Japan, the morbidity of post-HBV-related liver cirrhosis is about 13.9%.[1]In China, HBV related diseases is the most common primary reason for liver transplantation (78.6%).[2]Although liver transplantation can alleviate clinical symptoms such as ascites, hepatic encephalopathy, hypoalbuminemia, and infection, the adverse effects of immunosuppressive drugs raise the possibility of HBV recurrence or virus breakthrough.[3]Choosing the right prophylactic drug to control the HBV DNA load at an acceptable level is very important.

    Immunotherapy is a promising treatment that can enhance the body's ability to resist viruses. Traditional non-specific immune therapy is a passive one such as HBIG. Then studies have been concentrated onthe specific immune therapy for stimulating active immunity-vaccines. The development of new vaccines that stimulate an effective immune response when patients receive an organ transplant is a hot topic. Recently, Pan et al[4]synthesized engineered mAbs that showed inhibition of HBVin vitro.

    Various monotherapies and combinations have been developed for the treatment of hepatitis B.[5,6]These drugs have played important therapeutic roles, and they also have inherent disadvantages such as adverse reactions, hepatitis B recurrence, and long-term drugresistant strains. Viral resistance mechanisms and the pharmacoeconomics of combination therapy have been reported.[7]

    Immunotherapy

    Hepatitis B vaccination: dose and phase?

    Inducing an active immune response against the hepatitis B surface antigen (HBsAg) leads to continuous secretion of specific antibodies. The vaccine is given in either three or four separate doses as part of the existing routine immunization schedule. The safe anti-HBs titer for continuous prevention of HBV reinfection varies in some studies. Relatively low seroconversion rates and serum anti-HBs concentrations are reported among chronic HBV-infected liver transplantation recipients; only a minority of vaccines may have stable antibody levels >100 IU/L.[8]In the past, anti-HBs-positive individuals (seropositivity: anti-HBs titer of >10 IU/L) have always been considered safe to receive orthotopic liver transplantation for non-HBV-related diseases. Five of ninede novoHBV-infected patients were anti-HBs positive before orthotopic liver transplantation.[9]So, for prevention ofde novoHBV infection after transplantation, the protective anti-HBs titer should be >200 IU/L.[10]

    It has been reported that the response rate to HBV vaccine is significantly lower in patients with liver cirrhosis, immunocompromised patients, or organ transplant recipients.[8]When discussing immune status including T-cell and B-cell activity with response rate, Tahara et al[11]found that T-cell interactions which lead to an effective immune response to hepatitis B vaccination can cause activation of anti-HBsAg-specific T cells and suppression of anti-donor-specific T cells. Patients showing a donor-specific hyporesponse with a well-maintained response to a third-party (exogenous) stimulus always have a sustained immune response to the vaccine. Another study on T-cell immunity found that in 12 orthotopic liver transplantation recipients with HBV recurrence, the HBV-specific T-cell immunity was enhanced to a level comparable to that of patients with chronic hepatitis B, and the level was dependent on the serum viral load. Thus this raises an interesting question whether the higher response in theresearch of Tahara et al is really due to the donor-specific hyporesponse or just to the activity of anti-HBsAgspecific T cells or both. Schumann et al[12]demonstrated that HBV-specific humoral and cellular immunity can be transferred by liver transplantation after vaccination of the donor. The transfer of B-cell and T-cell immunity correlates with the magnitude of the immune responses in the donor.

    Table. Comparison of four studies of hepatitis B vaccination

    The response rate of liver transplantation candidates (with HBV-unrelated liver failure) to recombinant hepatitis B vaccination varies from 16% to 62%.[13]Many variables are associated with the response rate, the most important being the injection frequency and dose per injection. The Table shows four different studies of hepatitis B vaccination. Although these studies may be incompletely randomized or lack proper controls they show that 3-4 doses (40 μg), which can stimulate the necessarily response rate (30%-41%), are optimal for vaccination. But the HBsAb titer of responders varies a lot. Larger randomized controlled trials with good quality controls and design will provide more distinct answers about the dose, phase and response rate of hepatitis B vaccination.

    In special patients, the existing routine immunization schedules may not be equally effective as in normal people. Yamashiki et al[14]investigated 18 patients who underwent liver transplantation for chronic hepatitis B and 2 non-HBV-infected patients who received hepatitis B core antibody (HBcAb)-positive donor organs; doubledose double-phase use of second-generation recombinant vaccine was not effective in preventing hepatitis B recurrence in the study population. These populations should be targeted for a conventional vaccine regimen, and different approaches such as strong adjuvant or pre-S containing protein should be further tested.

    Vaccination also shows differences in sex, both in adult and pediatric liver transplantation groups. Girls respond with higher anti-HBs titres than boys, as do women.[18,19]It has become an interesting controversy whether the treatment is individualized to different ethnicities or groups of people. Ni et al[19]found that more than half of the children who were primarily vaccinated with HBV vaccines maintained adequate anti-HBs titers 1 year later after liver transplantation. All consecutive patients maintain a certain degree of cellular immune response irrespective of their anti-HBs status after liver transplantation. We expect that one or more doses of booster may help children who receive transplantation to develop protective response to anti-HBs.

    Human mAb: a novel approach?

    High specificity monoclonal antibodies to pathogens such as human papilloma virus have greatly expanded therapeutic methodology. Genetically engineered mAbs specific to the surface antigens of HBV would be a good alternative for the immunoprophylaxis of HBV infection.[20]Thus Pan et al[4]cloned the gene of a high Fab-affinity antibody from human peripheral blood and constructed Fab antibody rAAV-HB. After evaluating the activity of antibody hepatitis B in tree shrews treated with intramuscular injection of rAAV-HB andin vitroexperiments, they concluded that human antibody will be useful for the immunoprophylaxis of HBV infection, but this needs further study in human experiments. The safety and efficiency of transgenic drugs is controversial, which may restrict the use of engineered monoclonal antibodies.

    Drug regimens

    HBIG and lamivudine combination: low-dose intramuscular or high-dose intravenous HBIG?

    The HBIG (10 000 IU per month) and lamivudine regimen used to be the gold standard for prophylaxis against HBV recurrence after liver transplant. This therapy reduces the risk of recurrence to less than 5% at 5 years.[21]However, the cost of HBIG has driven people to investigate a lowdose of intramuscular HBIG (400-800 IU per month) and lamivudine in combination. This combination can achieve the same prophylaxis effect at a lower cost.[22]In Tashiro's research,[23]although two patients were preoperatively HBV DNA-positive shown by a transcription-mediated amplification assay method, all 14 patients receiving a high dose (10 000 IU/day) of HBIG and lamivudine in combination postoperatively became HBV-DNA-negative and HBsAg-negative.

    In Chinese liver transplant patients, the efficacy of HBIG was found to be associated with human leukocyte Fcγ receptor 3A gene polymorphisms (at nucleotide site 559). Among the 559G carrier group (n=42, 54.5%), the risk of HBV recurrence was 9.5%, and the 1- and 2-year recurrence-free survival rates were 95.2% and 88.7%, respectively. In the 559G noncarrier group (n=35, 45.5%), the risk of HBV recurrence was 28.6%, and the 1-and 2-year recurrence-free survival rates were 74.3% and 69.3%. Detecting FCGR3A genotypes can be a clinical reference for treatment before HBIG administration.[24]

    Hooman et al[25]pointed out that administration of intravenous HBIG (2000 IU per six weeks) and intramuscular administration of HBIG (2000 IU per six weeks) are equally effective with antibody against hepatitis B surface antigen (anti-HBs) in pharmacokinetics. Intramuscular HBIG may not be dose-saving; however, it may be cost-effective if the price per unit of intramuscular HBIG is lower. Individualized dosing intervals should be further evaluated as a cost-effective alternative to fixed dose schemes.

    Saab et al[26]compared prophylaxis with lamivudine and adefovir (strategy 1), with intramuscular HBIG and lamivudine (strategy 2) with the addition of adefovir in patients who subsequently developed hepatitis B recurrence. The medical costs for strategies 1 and 2 after 10 years of therapy were $151819 and $166246, respectively, and the cost saving was $14427. They developed a Markov model to provide pharmacoeconomic support for the use of strategy 1 as first-line therapy in hepatitis B prophylaxis in liver transplant recipients 1 year after transplantation. Strategy 1 not only decreased the total fee for preventing hepatitis B after liver transplantation, but also improved the quality of life. Administration of HBIG requires frequent blood tests to assess antibody titers. On the other hand, adefovir is an oral medication with rare adverse effects and less demand for frequent monitoring.

    High-dose HBIG during the ahepatic period and in the early stage of post transplantation can fulfill the treatment target as a long-term lamivudine therapy before liver transplantation. Long-term preoperative lamivudine treatment may result in an earlier HBV mutation in YMDD and increase the HBV recurrence rate and risk in the first year after transplantation.[27]Yilmaz et al[28]found that recurrence can be prevented in E-antigen-negative patients with HBIG alone or in E-antigen-positive patients with a combination of HBIG and an anti-viral agent. Eight out of fifteen E-antigen-positive patients who received HBIG alone developed recurrence after a mean of 17 months. As long as the anti-HBV surface remained detectable, no absolute minimum serum level appeared to lead to recurrent HBV. But the question is raised whether this combination or use of HBIG alone should be continued within 1 year after operation.

    Polyvalent immunoglobulin can cause nephrotoxicity. Pathologic examination of the kidneys generally reveals changes typical of osmotic nephrosis. The inappropriate use of HBIG can increase the risk of renal dysfunction, particularly in combination with nephrotoxic drugs.[29]

    Lamivudine and adefovir dipivoxil regimen: effective and easy to get

    Lamivudine and adefovir represent two different classes of anti-HBV agents (L-nucleoside and acyclic phosphonate) with different mechanisms of action, and there is no cross-resistance between them. Their combination greatly reduces the risk of subsequent adefovir resistance in nontransplantation patients.[30]Prophylaxis combined with adefovir/lamivudine therapy without the use of long-term HBIG is effective and well tolerated.[31]Meanwhile we cannot exclude the possibility that with a prolonged follow-up, some patients may experience viral breakthrough due to the appearance of lamivudine/adefovir resistance.[5]

    Before liver transplantation, lamivudine was proposed to be down-graded from the first to second-line therapy. In contrast, adefovir dipivoxil has been approved not only as the first-line therapy but also as rescue therapy for patients with lamivudine resistance.[32]A retrospective cohort study evaluated the safety and efficacy of adefovir in 68 elderly and cirrhotic patients with lamivudine-resistant chronic hepatitis B, among whom 75.4% received a combination treatment with lamivudine and adefovir for a median duration of 12.6 months; the remaining patients received adefovir overlapping with lamivudine treatment for a median duration of 7.9 months. At the end of the follow-up, 41.2% of the patients had undetectable HBV DNA (≤2000 copies/ml) with a median reduction of lg3.4 copies/ ml. No resistance mutations and no significant side effects were observed.[33]Even though no combination treatment can cover all the possible mutation strains, we focus on reducing the resistance as much as possible to get a good prognosis.

    A seven-year follow-up study of 24 patients showed that HBV recurrence developed in 7 patients with cumulative probabilities of 8%, 13%, 28%, 35%, 35%, and 49% in 1, 2, 3, 4, 5, and 6 years. Four patients had rtM204I mutation, and in 3 of them HBV DNA levels were too low for sequencing. After use of lamivudine followed by adefovir salvage for 150 weeks (91-193), 6 (86%) patients had normal ALT levels. HBV DNA was undetected in 2 (29%) patients, 100-1000 copies/ml in 2 (29%) and 10 000-100 000 copies/ml in 3 (43%) on the last visit. No genotypic resistance to adefovir was detected,[34]showing that lamivudine followed by adefovir salvage is effective for prophylaxis of recurrence of HBV for up to 7 years after liver transplantation.

    Management of YMDD mutant: lamivudine, adefovir and HBIG triple therapy

    YMDD mutation is common in the application of lamivudine in treating HBV. In 183 adult liver transplantation patients who lived more than 6 months and were followed up for 14.6 months, the rate of YMDD mutation in the lamivudine group was 8.49% (9/106), markedly higher than that in the lamivudine+HBIG group (1.30%, 1/77;P=0.035). The patients with YMDDmutation improved after treatment with adefovir.[35]

    4.烤箱預熱至160度,取烤盤、上置一烤架,雞置于烤架上(雞背向上),烤盤置于烤箱最下層,烘烤時間為每1000克雞烤35-40分鐘。每過45分鐘將烤盤中的湯汁和雞油,收集起來倒在另一盆內(nèi)。同時將雞翻一次身。

    In patients with YMDD mutation at the time of transplantation, combined use of HBIG and lamivudine is not consistently successful in preventing reinfection. In this situation, the addition of another antiviral agent combating the drug-resistant virus (i.e., adefovir, tenofovir, or entecavir) would be expected to further reduce the risk of prophylaxis failure.[36]

    As described in a ten-year study from Ikegami et al,[37]patients with YMDD mutation (9 of 29 patients), except an HBsAg-positive donor, were successfully protected by the triple therapy of lamivudine, adefovir, and HBIG. No graft loss was due to the recurrence of HBV. YMDD mutation should be closely monitored during lamivudine treatment.[38]

    Other oral nucleos(t)ide analogues: entecavir and tenofovir

    Entecavir is a guanosine nucleotide analogue. It is a new, highly potent antiviral agent; phase Ⅱ and Ⅲstudies have demonstrated this drug to be superior to placebo and lamivudine in patients with chronic HBV.[39]Because of the low resistance barrier, it used to be a substitute for lamivudine-resistant patients. Kurashige et al[40]recommended that lamivudine-to-entecavir switching treatment may be suitable in chronic hepatitis B patients without evidence of lamivudine resistance during the preceding lamivudine treatment with great attention to the emergence of entecavir-resistance.

    Kamar et al[41]reported that 10 male transplant patients with chronic HBV infection who were adefovir-(n=9) or lamivudine-resistant (n=1) were given entecavir at 0.5 to 1 mg/d. All patients were HBsAg-positive. After a median follow-up of 16.5 months, entecavir therapy reduced the HBV DNA viral load from lg3.86 (lg2.71-lg6.46) copies/ml at baseline to lg2.94 (lg2.15-lg4) copies/ml at the last follow-up (P=0.004). The host biological response was better in kidney transplant patients than in liver transplant patients because HBV has a liver tropism which may be more resistant and more aggressive in a transplanted liver than in a native one.[41]This study showed good results of entecavir in treating kidney or liver transplant patients, which may be used in treatment of liver-kidney transplantation patients.

    Tenofovir is an acyclic nucleotide analog, reverse transcriptase inhibitor.[42]Zhu et al[43]compared different regimens of tenofovir with lamivudine, entecavir, and adefovir. They found that of combinations lamivudine+tenofovir, entecavir+tenofovir, and adefovir+ tenofovir showed additive anti-HBV effectsin vitro. This supports the use of tenofovir as a component in combination regimens with currently available anti-HBV nucleoside analogues.

    Benefits and risks of combination therapy

    Many reports describe the benefits and risks of hepatitis B drug treatment. This section just mentions some special points of liver transplantation. Combination therapy for hepatitis B is recommended in specific patients: those who have undergone liver transplantation, those with decompensated cirrhosis, those coinfected with human immunodeficiency virus and HBV who are on antiretroviral therapy, and those with drug-resistant HBV infection.[44]In successful antiviral combination therapy, different drug regimens may cover major virus mutation pathways to minimize possible drug resistance. However, investigators still find many different mutations in response to the first line drugs such as lamivudine with rtM204V, rtL180M, and rtS202G mutations.[40]These mutations may cause virus recurrence and lead to transplant failure. Thus it is important to monitor the status of patients during therapy. Monitoring of treatment response includes tests for serum aminotransferase level, HBV DNA level, hepatitis B e antigen (HBeAg) and antibody (anti-HBe), hepatitis B surface antigen (HBsAg) or antibody (anti-HBs), and liver histology.[45]Early discovery of possible drug resistance may contribute to a good prognosis of liver transplantation.

    Genetic factors and drug therapy: individual treatment

    Eight distinct genotypes of HBV A to H have been identified, each having a characteristic geographic distribution.[46,47]Each genotype can be divided into many subtypes like B1-B4, and C1-C4. In China, B2 and C2 predominate.[48]Genotype can effect graft survival rate and the cumulative rate of viral breakthrough. Lo et al[49]found that genotype B patients have more pre-transplant acute flare, poorer liver functions, and higher end-stage liver disease scores. Fewer genotype B patients have HBeAg (13% vs. 32%;P=0.017). The 3-year graft survival rate is 83% for genotype B and 89% for genotype C (P=0.2). The graft survival due to lamivudine-resistant mutation at 3 years is 4% for genotype B and 21% for genotype C (P=0.017). Liver biopsy after viral breakthrough showed recurrent hepatitis B in 7 of 10 genotype C patients.

    Gene polymorphism also contributes to host immune behavior to HBV and drugs, such as mutations of the gene coding for the major hydrophilic region of HBsAg may be associated with anti-HBs immunoglobulins or vaccine escape.[50]In Chinese liver transplantation, the organ recipients with CTLA-4 +49 GG genotype have a reduced risk (6.67%,n=11) of HBV recurrence comparedwith non-CTLA-4 +49 GG-carrying individuals (20.7%) (relative risk 3.098;P=0.032).[51]

    After ending of the human genome project, the concept of molecular medicine has emerged. The evidence mentioned above can lead to early diagnosis and genetic prediction of HBV infection or recurrence. Before prescribing a drug in future we may review the genetic characteristics of a patient and decide the best choice of therapy.

    In conclusion, further research is needed to provide evidence-based recommendations about optimal antiviral therapy in adults with chronic hepatitis B infection. Monoclonal antibodies are still in the experimental stage, and the next step is taken to do relevant animal and human studies. A consensus on a standard regimen for the treatment of hepatitis B should be achieved.

    Funding:This study was supported by grants from the Key Program of National Natural Science Foundation of China (30730085) and the National High Technology Research and Development Program of China (863 Program; 2006AA 02A412).

    Ethical approval:Not needed.

    Contributors:ZJ wrote the main body of the article under the supervision of ZL and ZSS. ZL and ZSS provided advice on medical aspects. ZSS is the guarantor.

    Competing interest:No bene fits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

    1 Michitaka K, Nishiguchi S, Aoyagi Y, Hiasa Y, Tokumoto Y, Onji M, et al. Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol 2009.

    2 Zhao J, Yan L, Li B, Zeng Y, Wen T, Zhao J, et al. Diabetes mellitus after living donor liver transplantation: data from mainland China. Transplant Proc 2009;41:1756-1760.

    3 Lok AS. How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting. Liver Transpl 2008;14:S8-S14.

    4 Pan T, Cai M, Tang L, Zhou LQ, Li BJ, Zhu T, et al. A novel approach of prophylaxis to HBV recurrence after liver transplantation. Virology 2008;382:1-9.

    5 Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008;48:1460-1466.

    6 Zhang FK, Zhang Y, Zhang JY, Jia JD, Wang BE. Favorable outcome of de novo hepatitis B infection after liver transplantation with lamivudine and adefovir therapy. Transpl Infect Dis 2009;11:549-552.

    7 Avolio AW, Nure E, Pompili M, Barbarino R, Basso M, Caccamo L, et al. Liver transplantation for hepatitis B virus patients: long-term results of three therapeutic approaches. Transplant Proc 2008;40:1961-1964.

    8 Castells L, Esteban R. Hepatitis B vaccination in liver transplant candidates. Eur J Gastroenterol Hepatol 2001;13:359-361.

    9 Bárcena Marugán R, García-Hoz F, Vázquez Romero M, Nash R, Mateos M, González Alonso R, et al. Prevention of de novo hepatitis B infection in liver allograft recipients with previous hepatitis B infection or hepatitis B vaccination. Am J Gastroenterol 2002;97:2398-2401.

    10 Su WJ, Ho MC, Ni YH, Chen HL, Hu RH, Wu YM, et al. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection. J Pediatr Gastroenterol Nutr 2009;48:203-208.

    11 Tahara H, Tanaka Y, Ishiyama K, Ide K, Shishida M, Irei T, et al. Successful hepatitis B vaccination in liver transplant recipients with donor-specific hyporesponsiveness. Transpl Int 2009;22: 805-813.

    12 Schumann A, Lindemann M, Valentin-Gamazo C, Lu M, Elmaagacli A, Dahmen U, et al. Adoptive immune transfer of hepatitis B virus specific immunity from immunized living liver donors to liver recipients. Transplantation 2009;87:103-111.

    13 Takemura N, Sugawara Y, Tamura S, Makuuchi M. Liver transplantation using hepatitis B core antibody-positive grafts: review and university of Tokyo experience. Dig Dis Sci 2007; 52:2472-2477.

    14 Yamashiki N, Sugawara Y, Tamura S, Kaneko J, Matsui Y, Togashi J, et al. Double-dose double-phase use of second generation hepatitis B virus vaccine in patients after living donor liver transplantation: Not an effective measure in transplant recipients. Hepatol Res 2009;39:7-13.

    15 Pascasio JM, AoufiS, Gash A, Sousa JM, Perea R, Sayago M, et al. Response to a vaccination schedule with 4 doses of 40 microg against hepatitis B virus in cirrhotic patients evaluated for liver transplantation. Transplant Proc 2008;40:2943-2945.

    16 Bonazzi PR, Bacchella T, Freitas AC, Osaki KT, Lopes MH, Freire MP, et al. Double-dose hepatitis B vaccination in cirrhotic patients on a liver transplant waiting list. Braz J Infect Dis 2008;12:306-309.

    17 Jin SJ, Lu SC, Lai W, Dai J, Zhao J, Li YP, et al. Enhancing active immunity against hepatitis B virus by HBV vaccine immunization in patients with HBV-related end-stage liver diseases treated with liver transplantation. Zhonghua Gan Zang Bing Za Zhi 2008;16:261-264.

    18 Fang JW, Lai CL, Chung HT, Wu PC, Lau JY. Female children respond to recombinant hepatitis B vaccine with a higher titre than male. J Trop Pediatr 1994;40:104-107.

    19 Ni YH, Ho MC, Wu JF, Chen HL, Wu YM, Hu RH, et al. Response to booster hepatitis B vaccines in liver-transplanted children primarily vaccinated in infancy. Transplantation 2008;86:1531-1535.

    20 Hong HJ, Ryu CJ, Hur H, Kim S, Oh HK, Oh MS, et al. In vivo neutralization of hepatitis B virus infection by an anti-preS1 humanized antibody in chimpanzees. Virology 2004;318:134-141.

    21 Papatheodoridis GV, Cholongitas E, Archimandritis AJ, Burroughs AK. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int 2009; 29:1294-1305.

    22 Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000;6:429-433.

    23 Tashiro H, Itamoto T, Fudaba Y, Ohdan H, Fukuda S, KohashiT, et al. Prophylaxis against recurrence of HBV hepatitis after living-donor liver transplantation. Hepatogastroenterology 2008;55:1746-1749.

    24 Wang WL, Zhang GL, Wu LH, Yao MY, Jin J, Jia CK, et al. Efficacy of hepatitis B immunoglobulin in relation to the gene polymorphisms of human leukocyte Fcgamma receptor III (CD16) in Chinese liver transplant patients. Chin Med J (Engl) 2007;120:1606-1610.

    25 Hooman N, Rifai K, Hadem J, Vaske B, Philipp G, Priess A, et al. Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl 2008;14:435-442.

    26 Saab S, Ham MY, Stone MA, Holt C, Tong M. Decision analysis model for hepatitis B prophylaxis one year after liver transplantation. Liver Transpl 2009;15:413-420.

    27 Lu AW, Zheng SS, Wu MP, Shen Y, Yang RW. Reevaluation of the effect of lamivudine therapy preoperative to prevent HBV recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2008;7:357-361.

    28 Yilmaz N, Shiffman ML, Todd Stravitz R, Sterling RK, Luketic VA, Sanyal AJ, et al. Prophylaxsis against recurrance of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years. Liver Int 2008;28:72-78.

    29 Angeli P, Scaglione F. Nephrotoxicity of intravenous immunoglobulin in the setting of liver transplantation or HBV-related cirrhosis: an undervalued topic. Minerva Gastroenterol Dietol 2008;54:259-275.

    30 Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007;133:1445-1451.

    31 Patterson SJ, Angus PW. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues. Curr Opin Organ Transplant 2009;14:225-230.

    32 Jiang L, Jiang LS, Cheng NS, Yan LN. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 2009;15:2489-2499.

    33 Zoulim F, Parvaz P, Marcellin P, Zarski JP, Beaugrand M, Benhamou Y, et al. Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure. Liver Int 2009;29:420-426.

    34 Limquiaco JL, Wong J, Wong VW, Wong GL, Tse CH, Chan HY, et al. Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study. J Med Virol 2009;81:224-229.

    35 Zhang XL, Zhu XF, Shi HJ, Cui SZ, Tang YQ, Ba MC, et al. Prevention and treatment of hepatitis B recurrence after liver transplantation. Zhonghua Yi Xue Za Zhi 2008;88:606-609.

    36 Samuel D. The option of liver transplantation for hepatitis B: where are we? Dig Liver Dis 2009;41:S185-189.

    37 Ikegami T, Soejima Y, Ohta R, Taketomi A, Yoshizumi T, Harada N, et al. Living donor liver transplantation for hepatitis B associated liver diseases: a 10-year experience in a single center. Hepatogastroenterology 2008;55:1445-1449.

    38 Gwak GY, Huh W, Lee DH, Choi MS, Lee JH, Koh KC, et al. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy. Transplant Proc 2007;39: 3121-3126.

    39 Calleja JL, Penas B. Enferm Infecc Microbiol Clin 2008;26:S39-48.

    40 Kurashige N, Ohkawa K, Hiramatsu N, Yakushijin T, Mochizuki K, Oze T, et al. Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance. J Gastroenterol 2009;44:864-870.

    41 Kamar N, Milioto O, Alric L, El Kahwaji L, Cointault O, Lavayssière L, et al. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008;86:611-614.

    42 Reynaud L, Carleo MA, Talamo M, Borgia G. Tenofovir and its potential in the treatment of hepatitis B virus. Ther Clin Risk Manag 2009;5:177-185.

    43 Zhu Y, Curtis M, Qi X, Miller MD, Borroto-Esoda K. Antihepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues. Antivir Chem Chemother 2009;19:165-176.

    44 Terrault NA. Benefits and risks of combination therapy for hepatitis B. Hepatology 2009;49:S122-128.

    45 Andersson KL, Chung RT. Monitoring during and after antiviral therapy for hepatitis B. Hepatology 2009;49:S166-173.

    46 Fung SK, Lok AS. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 2004;40: 790-792.

    47 Echevarría JM, Avellón A. Hepatitis B virus genetic diversity. J Med Virol 2006;78:S36-42.

    48 Norder H, Couroucé AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004;47:289-309.

    49 Lo CM, Cheung CK, Lau GK, Yuen MF, Liu CL, Chan SC, et al. Significance of hepatitis B virus genotype in liver transplantation for chronic hepatitis B. Am J Transplant 2005; 5:1893-1900.

    50 Roque-Afonso AM, Ferey MP, Belkhiri D, Dussaix E. HBs antigen mutants: prevalence, clinical and diagnostic implications. Pathol Biol (Paris) 2005;53:563-568.

    51 Jiang Z, Feng X, Zhang W, Gao F, Ling Q, Zhou L, et al. Recipient cytotoxic T lymphocyte antigen-4 +49 G/G genotype is associated with reduced incidence of hepatitis B virus recurrence after liver transplantation among Chinese patients. Liver Int 2007;27:1202-1208.

    October 22, 2009

    Accepted after revision December 23, 2009

    Author Affiliations: Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health; Key Laboratory of Organ Transplantation, Zhejiang Province; First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China (Zhang J, Zhouland Zheng SS)

    Shu-Sen Zheng, MD, PhD, FACS, Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China (Tel: 86-571-87236601; Email: shusenzheng@zju.edu.cn)

    ? 2010, Hepatobiliary Pancreat Dis Int. All rights reserved.

    亚洲激情在线av| 午夜福利在线在线| 99久久精品热视频| 欧美日韩中文字幕国产精品一区二区三区| 69av精品久久久久久| 国产人妻一区二区三区在| 老司机福利观看| 丁香六月欧美| 在线天堂最新版资源| 国产午夜精品久久久久久一区二区三区 | 欧美一区二区精品小视频在线| 欧美bdsm另类| 亚洲美女黄片视频| av天堂在线播放| 久久中文看片网| 欧美成人性av电影在线观看| 热99re8久久精品国产| 久久久久精品国产欧美久久久| 国产精品99久久久久久久久| 一进一出抽搐gif免费好疼| 久久这里只有精品中国| 国产精品女同一区二区软件 | 老司机午夜十八禁免费视频| 国产 一区 欧美 日韩| 少妇熟女aⅴ在线视频| 日韩人妻高清精品专区| 99久久精品热视频| 欧美成人性av电影在线观看| 国产日本99.免费观看| 欧美一级a爱片免费观看看| 成人国产综合亚洲| 亚洲真实伦在线观看| 欧美黑人欧美精品刺激| 欧美黑人巨大hd| 久久精品国产99精品国产亚洲性色| 可以在线观看毛片的网站| 国产精品1区2区在线观看.| 国内少妇人妻偷人精品xxx网站| 草草在线视频免费看| 亚洲av一区综合| 午夜激情欧美在线| 国产探花在线观看一区二区| 国产老妇女一区| 国产野战对白在线观看| 国产欧美日韩一区二区三| 十八禁网站免费在线| 我要看日韩黄色一级片| 男插女下体视频免费在线播放| 国产单亲对白刺激| 看片在线看免费视频| 一区二区三区激情视频| 无遮挡黄片免费观看| 国产精品av视频在线免费观看| 床上黄色一级片| 欧美成人a在线观看| 一级av片app| 国产亚洲精品综合一区在线观看| 国产免费一级a男人的天堂| 亚洲精品成人久久久久久| 婷婷精品国产亚洲av在线| 精品乱码久久久久久99久播| 国产精品久久久久久人妻精品电影| 性欧美人与动物交配| 18+在线观看网站| 99视频精品全部免费 在线| 深夜a级毛片| 黄色视频,在线免费观看| 简卡轻食公司| 久久久精品大字幕| 国产视频一区二区在线看| 国内揄拍国产精品人妻在线| 69人妻影院| 又爽又黄无遮挡网站| 9191精品国产免费久久| 悠悠久久av| 美女高潮喷水抽搐中文字幕| 国产精品久久久久久人妻精品电影| 国产v大片淫在线免费观看| 国产伦在线观看视频一区| 久久欧美精品欧美久久欧美| 哪里可以看免费的av片| 美女cb高潮喷水在线观看| 丰满人妻熟妇乱又伦精品不卡| 欧美激情久久久久久爽电影| 最好的美女福利视频网| 久久久精品欧美日韩精品| 精品人妻熟女av久视频| 免费观看精品视频网站| 午夜福利在线观看免费完整高清在 | 他把我摸到了高潮在线观看| 久久久久久大精品| 亚洲欧美日韩高清专用| 久久久久久久亚洲中文字幕 | 亚洲成av人片免费观看| 老师上课跳d突然被开到最大视频 久久午夜综合久久蜜桃 | 久久99热这里只有精品18| 91久久精品国产一区二区成人| 久久精品国产99精品国产亚洲性色| 国产熟女xx| 精品人妻1区二区| 噜噜噜噜噜久久久久久91| 非洲黑人性xxxx精品又粗又长| 国产欧美日韩精品一区二区| 成人毛片a级毛片在线播放| 一二三四社区在线视频社区8| 精品久久久久久久末码| 精品久久久久久成人av| 亚洲av二区三区四区| 最好的美女福利视频网| 国内毛片毛片毛片毛片毛片| x7x7x7水蜜桃| 9191精品国产免费久久| 亚洲精品一区av在线观看| 最近视频中文字幕2019在线8| 非洲黑人性xxxx精品又粗又长| 久久久久久久久中文| 又粗又爽又猛毛片免费看| 国产亚洲欧美在线一区二区| bbb黄色大片| 小蜜桃在线观看免费完整版高清| 国产爱豆传媒在线观看| 国产一区二区激情短视频| 欧美日韩国产亚洲二区| 国产午夜精品久久久久久一区二区三区 | 久久久国产成人精品二区| 看黄色毛片网站| 日韩免费av在线播放| 成年女人永久免费观看视频| 能在线免费观看的黄片| 国产在线男女| 亚洲精品在线观看二区| 亚洲狠狠婷婷综合久久图片| 给我免费播放毛片高清在线观看| av在线老鸭窝| 999久久久精品免费观看国产| 国产成年人精品一区二区| 在现免费观看毛片| 脱女人内裤的视频| 亚洲专区中文字幕在线| a级毛片免费高清观看在线播放| 99riav亚洲国产免费| 色尼玛亚洲综合影院| 日韩国内少妇激情av| 日韩成人在线观看一区二区三区| 最近中文字幕高清免费大全6 | 成人鲁丝片一二三区免费| 国产精品亚洲美女久久久| 亚洲国产精品sss在线观看| 免费大片18禁| 国产日本99.免费观看| 国产午夜精品论理片| 丁香欧美五月| 久久6这里有精品| 亚洲avbb在线观看| 国语自产精品视频在线第100页| 日韩欧美一区二区三区在线观看| 亚洲欧美清纯卡通| 亚洲三级黄色毛片| 91久久精品电影网| 欧美性猛交黑人性爽| 97超级碰碰碰精品色视频在线观看| 久久久久免费精品人妻一区二区| 国产精品久久久久久亚洲av鲁大| 国产成年人精品一区二区| 日本 欧美在线| 亚洲avbb在线观看| 亚洲va日本ⅴa欧美va伊人久久| 97人妻精品一区二区三区麻豆| 岛国在线免费视频观看| 久久伊人香网站| 小说图片视频综合网站| 久久这里只有精品中国| 99riav亚洲国产免费| 国产色婷婷99| 91久久精品电影网| 色综合站精品国产| 成年免费大片在线观看| 国内精品一区二区在线观看| 国产免费av片在线观看野外av| 高清毛片免费观看视频网站| 日韩大尺度精品在线看网址| 亚洲av成人不卡在线观看播放网| 深爱激情五月婷婷| 欧美日韩亚洲国产一区二区在线观看| 三级男女做爰猛烈吃奶摸视频| 亚州av有码| 狂野欧美白嫩少妇大欣赏| 久久久久免费精品人妻一区二区| 色噜噜av男人的天堂激情| 日韩高清综合在线| 成人欧美大片| 亚洲美女黄片视频| 99久久无色码亚洲精品果冻| 久久国产精品人妻蜜桃| 亚洲专区中文字幕在线| 国产黄色小视频在线观看| 色尼玛亚洲综合影院| 精品一区二区三区人妻视频| 久久久精品欧美日韩精品| 色综合欧美亚洲国产小说| 波野结衣二区三区在线| 亚洲18禁久久av| x7x7x7水蜜桃| 白带黄色成豆腐渣| 深夜精品福利| 亚洲人成伊人成综合网2020| 天天一区二区日本电影三级| 久久婷婷人人爽人人干人人爱| 亚洲最大成人手机在线| 国产亚洲精品av在线| 国产不卡一卡二| 男插女下体视频免费在线播放| a级一级毛片免费在线观看| 日本与韩国留学比较| 免费搜索国产男女视频| 亚洲av成人精品一区久久| ponron亚洲| 欧美日韩中文字幕国产精品一区二区三区| 国内精品久久久久久久电影| 日本熟妇午夜| 美女黄网站色视频| 一进一出抽搐动态| 国产探花极品一区二区| 高清日韩中文字幕在线| 久久午夜亚洲精品久久| 久久国产精品人妻蜜桃| 亚洲精品在线观看二区| 久久亚洲真实| 日日夜夜操网爽| 一级a爱片免费观看的视频| 色精品久久人妻99蜜桃| 亚洲三级黄色毛片| 2021天堂中文幕一二区在线观| 男女视频在线观看网站免费| 啦啦啦韩国在线观看视频| 亚洲自拍偷在线| 成人无遮挡网站| 亚洲欧美日韩高清在线视频| 亚洲真实伦在线观看| 色精品久久人妻99蜜桃| 国产激情偷乱视频一区二区| 亚洲精品成人久久久久久| 国产亚洲精品久久久com| 91在线观看av| 国产蜜桃级精品一区二区三区| 成人性生交大片免费视频hd| 国产大屁股一区二区在线视频| 亚洲av成人不卡在线观看播放网| 毛片一级片免费看久久久久 | av视频在线观看入口| 国产精品一区二区免费欧美| av中文乱码字幕在线| 日韩欧美精品免费久久 | 国产一区二区三区在线臀色熟女| 日本在线视频免费播放| 91久久精品电影网| 亚洲av熟女| 亚洲av不卡在线观看| 在线观看66精品国产| 有码 亚洲区| 精品日产1卡2卡| 成人毛片a级毛片在线播放| 日本a在线网址| 老女人水多毛片| 国产野战对白在线观看| 十八禁人妻一区二区| netflix在线观看网站| 国产蜜桃级精品一区二区三区| 日韩有码中文字幕| 亚洲无线观看免费| 午夜福利在线在线| 精品免费久久久久久久清纯| 又爽又黄a免费视频| 亚洲中文字幕一区二区三区有码在线看| 国产精品日韩av在线免费观看| 老司机午夜福利在线观看视频| 国产精品亚洲一级av第二区| 我要看日韩黄色一级片| 天堂影院成人在线观看| 嫩草影视91久久| 91久久精品国产一区二区成人| 99久久精品一区二区三区| 3wmmmm亚洲av在线观看| 国产欧美日韩一区二区精品| 一本综合久久免费| 五月玫瑰六月丁香| 美女高潮的动态| 亚洲人成网站在线播放欧美日韩| 黄色视频,在线免费观看| 在线播放国产精品三级| 国产三级中文精品| 天天躁日日操中文字幕| 窝窝影院91人妻| 精品久久久久久久久亚洲 | 最新在线观看一区二区三区| 全区人妻精品视频| 超碰av人人做人人爽久久| 国产色爽女视频免费观看| 2021天堂中文幕一二区在线观| 性色avwww在线观看| 日日摸夜夜添夜夜添av毛片 | 欧美一区二区亚洲| 国产aⅴ精品一区二区三区波| 亚洲成人精品中文字幕电影| 午夜免费激情av| 国产精品亚洲美女久久久| 国产私拍福利视频在线观看| 日韩有码中文字幕| 人人妻人人看人人澡| 亚洲美女黄片视频| 一本久久中文字幕| 成人高潮视频无遮挡免费网站| 深夜精品福利| 婷婷丁香在线五月| 色哟哟哟哟哟哟| 日韩av在线大香蕉| 成人一区二区视频在线观看| 婷婷精品国产亚洲av在线| 在线观看午夜福利视频| 在线播放无遮挡| 我的女老师完整版在线观看| 两人在一起打扑克的视频| 熟女电影av网| 少妇裸体淫交视频免费看高清| 亚洲欧美日韩高清在线视频| 久久国产乱子免费精品| 一级作爱视频免费观看| 在线a可以看的网站| 俄罗斯特黄特色一大片| 看免费av毛片| 欧美bdsm另类| 日本撒尿小便嘘嘘汇集6| 激情在线观看视频在线高清| 色综合站精品国产| 午夜久久久久精精品| 美女大奶头视频| 欧美色视频一区免费| 国产精品亚洲美女久久久| 精品乱码久久久久久99久播| 免费看日本二区| 中文字幕av成人在线电影| 久久天躁狠狠躁夜夜2o2o| 亚洲国产日韩欧美精品在线观看| 国产精品免费一区二区三区在线| 成熟少妇高潮喷水视频| 国产爱豆传媒在线观看| 男人的好看免费观看在线视频| 真人做人爱边吃奶动态| 我的女老师完整版在线观看| 欧美丝袜亚洲另类 | 精品人妻偷拍中文字幕| а√天堂www在线а√下载| 亚洲av中文字字幕乱码综合| 丰满的人妻完整版| 成熟少妇高潮喷水视频| 波多野结衣高清无吗| 美女cb高潮喷水在线观看| 亚洲欧美日韩东京热| 舔av片在线| 淫妇啪啪啪对白视频| 少妇被粗大猛烈的视频| 色视频www国产| 悠悠久久av| 97热精品久久久久久| 老熟妇乱子伦视频在线观看| a级毛片a级免费在线| 九色国产91popny在线| avwww免费| 久9热在线精品视频| 日韩精品中文字幕看吧| 长腿黑丝高跟| 真实男女啪啪啪动态图| 精品久久久久久久久亚洲 | 久久人妻av系列| eeuss影院久久| 久久久国产成人精品二区| 成人毛片a级毛片在线播放| 男人的好看免费观看在线视频| 国产精品国产高清国产av| 一个人免费在线观看的高清视频| 高潮久久久久久久久久久不卡| 国产精品av视频在线免费观看| 蜜桃亚洲精品一区二区三区| 国产爱豆传媒在线观看| 成人午夜高清在线视频| 91在线观看av| 日韩欧美一区二区三区在线观看| 特大巨黑吊av在线直播| 人人妻,人人澡人人爽秒播| 在现免费观看毛片| 国产精品久久久久久久电影| 亚洲av熟女| 亚洲午夜理论影院| 天堂动漫精品| 九色国产91popny在线| 男女下面进入的视频免费午夜| xxxwww97欧美| 99久久久亚洲精品蜜臀av| 男女视频在线观看网站免费| 亚洲中文日韩欧美视频| 99热只有精品国产| 亚洲精品乱码久久久v下载方式| 亚洲精品一区av在线观看| 欧美日韩福利视频一区二区| 变态另类成人亚洲欧美熟女| 欧美zozozo另类| 成人精品一区二区免费| 欧美黄色片欧美黄色片| 直男gayav资源| 精品人妻视频免费看| 亚洲人与动物交配视频| 日本黄大片高清| 精品久久久久久久末码| 国产伦在线观看视频一区| 中文字幕熟女人妻在线| 又黄又爽又刺激的免费视频.| 搡老岳熟女国产| 18禁黄网站禁片午夜丰满| 全区人妻精品视频| 色播亚洲综合网| 国产毛片a区久久久久| 琪琪午夜伦伦电影理论片6080| 老师上课跳d突然被开到最大视频 久久午夜综合久久蜜桃 | 丰满乱子伦码专区| 亚洲在线观看片| 精品乱码久久久久久99久播| 性欧美人与动物交配| 人人妻,人人澡人人爽秒播| 欧美xxxx性猛交bbbb| 动漫黄色视频在线观看| 亚洲五月婷婷丁香| 在线a可以看的网站| 一区二区三区免费毛片| 在线十欧美十亚洲十日本专区| 天美传媒精品一区二区| 亚洲一区二区三区不卡视频| 国产精品精品国产色婷婷| 波多野结衣巨乳人妻| 久久久久久久午夜电影| 999久久久精品免费观看国产| 草草在线视频免费看| 校园春色视频在线观看| 久久精品国产自在天天线| 蜜桃亚洲精品一区二区三区| 精华霜和精华液先用哪个| 99热这里只有是精品在线观看 | 热99re8久久精品国产| 日本黄大片高清| 久久性视频一级片| 欧美三级亚洲精品| 国产精品久久视频播放| .国产精品久久| 亚洲欧美日韩卡通动漫| 可以在线观看毛片的网站| 久久中文看片网| 老司机福利观看| 3wmmmm亚洲av在线观看| 蜜桃亚洲精品一区二区三区| 久久国产乱子伦精品免费另类| 首页视频小说图片口味搜索| 亚洲成人免费电影在线观看| 午夜免费激情av| 亚洲精品在线美女| 精品久久久久久久末码| 九九在线视频观看精品| 久久午夜福利片| 三级男女做爰猛烈吃奶摸视频| 毛片一级片免费看久久久久 | 成人永久免费在线观看视频| 欧美一区二区亚洲| 国产午夜精品论理片| 国产伦人伦偷精品视频| 国产免费男女视频| а√天堂www在线а√下载| 日本熟妇午夜| 老鸭窝网址在线观看| 亚洲精品一卡2卡三卡4卡5卡| 亚洲aⅴ乱码一区二区在线播放| 欧美绝顶高潮抽搐喷水| av在线天堂中文字幕| 国产亚洲精品av在线| 极品教师在线免费播放| 欧美日本视频| 噜噜噜噜噜久久久久久91| 国产亚洲精品av在线| 俄罗斯特黄特色一大片| 在线观看舔阴道视频| 中文字幕熟女人妻在线| 夜夜躁狠狠躁天天躁| 变态另类丝袜制服| 欧美潮喷喷水| 精品久久久久久久久av| 日本一本二区三区精品| 免费电影在线观看免费观看| 午夜精品一区二区三区免费看| 88av欧美| 天堂网av新在线| 天堂动漫精品| 久久久精品大字幕| 国产成人福利小说| 欧美潮喷喷水| 国产一区二区亚洲精品在线观看| 天堂av国产一区二区熟女人妻| 久久人人爽人人爽人人片va | 在线观看免费视频日本深夜| 欧美黑人巨大hd| 夜夜看夜夜爽夜夜摸| 97热精品久久久久久| 99视频精品全部免费 在线| 久久午夜福利片| 国产亚洲精品久久久久久毛片| 18禁裸乳无遮挡免费网站照片| 在线观看免费视频日本深夜| 久久久久国内视频| 欧美三级亚洲精品| 久99久视频精品免费| 好男人电影高清在线观看| 欧美日韩福利视频一区二区| ponron亚洲| 老司机午夜十八禁免费视频| 午夜免费成人在线视频| 日本撒尿小便嘘嘘汇集6| 国产av在哪里看| 欧美中文日本在线观看视频| 3wmmmm亚洲av在线观看| av黄色大香蕉| 国产精品免费一区二区三区在线| 国产高清三级在线| 久久久久久久久久黄片| 精品国内亚洲2022精品成人| 午夜福利免费观看在线| 亚洲av中文字字幕乱码综合| 午夜福利免费观看在线| 久久久久免费精品人妻一区二区| 精品免费久久久久久久清纯| 国产精品国产高清国产av| 中国美女看黄片| 人妻夜夜爽99麻豆av| 日韩有码中文字幕| 午夜福利18| 成年女人毛片免费观看观看9| 久久精品夜夜夜夜夜久久蜜豆| 真实男女啪啪啪动态图| 九色成人免费人妻av| 国产亚洲精品av在线| 日日干狠狠操夜夜爽| 在线观看66精品国产| 99在线视频只有这里精品首页| 亚洲av成人不卡在线观看播放网| 婷婷丁香在线五月| 亚洲综合色惰| 天堂网av新在线| 欧美性猛交╳xxx乱大交人| 欧美乱色亚洲激情| 亚洲五月天丁香| 欧美日韩黄片免| xxxwww97欧美| 自拍偷自拍亚洲精品老妇| 欧美成人免费av一区二区三区| 久久99热这里只有精品18| 亚洲在线观看片| 亚洲性夜色夜夜综合| 国产精品乱码一区二三区的特点| 嫩草影院入口| 一区二区三区高清视频在线| 老司机午夜十八禁免费视频| avwww免费| 亚洲在线自拍视频| 亚洲av电影在线进入| 成人国产综合亚洲| 97热精品久久久久久| 精品一区二区三区视频在线观看免费| 欧美成狂野欧美在线观看| 日本五十路高清| 午夜福利成人在线免费观看| av欧美777| 脱女人内裤的视频| 中文字幕熟女人妻在线| 国产黄片美女视频| 国产精品嫩草影院av在线观看 | 熟女电影av网| 能在线免费观看的黄片| 精品人妻视频免费看| 内地一区二区视频在线| 久久99热这里只有精品18| 欧美潮喷喷水| 两性午夜刺激爽爽歪歪视频在线观看| 国产高清有码在线观看视频| 国产精品久久久久久久电影| 在线看三级毛片| 亚洲美女视频黄频| av专区在线播放| 午夜亚洲福利在线播放| 国产亚洲精品久久久久久毛片| 熟女人妻精品中文字幕| 亚洲成人精品中文字幕电影| 亚洲天堂国产精品一区在线| 久久久久久久午夜电影| 白带黄色成豆腐渣| 成人性生交大片免费视频hd| 人人妻人人澡欧美一区二区| 午夜福利成人在线免费观看| 亚洲国产欧洲综合997久久,| 日日摸夜夜添夜夜添小说| 久久久久久久精品吃奶| 亚洲成人久久性| 欧美3d第一页| 亚洲av免费在线观看| 在线播放无遮挡| www.www免费av| 国产av在哪里看| 色尼玛亚洲综合影院| a级毛片免费高清观看在线播放| 免费无遮挡裸体视频| 麻豆成人午夜福利视频|